Standardized guinea pig model for Q fever vaccine reactogenicity.
Historically, vaccination with Coxiella burnetii whole cell vaccines has induced hypersensitivity reactions in humans and animals that have had prior exposure to the pathogen as a result of infection or vaccination. Intradermal skin testing is routinely used to evaluate exposure in humans, and guine...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0205882 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849317095426228224 |
|---|---|
| author | Laurie A Baeten Brendan K Podell Ann E Sluder Anja Garritsen Richard A Bowen Mark C Poznansky |
| author_facet | Laurie A Baeten Brendan K Podell Ann E Sluder Anja Garritsen Richard A Bowen Mark C Poznansky |
| author_sort | Laurie A Baeten |
| collection | DOAJ |
| description | Historically, vaccination with Coxiella burnetii whole cell vaccines has induced hypersensitivity reactions in humans and animals that have had prior exposure to the pathogen as a result of infection or vaccination. Intradermal skin testing is routinely used to evaluate exposure in humans, and guinea pig hypersensitivity models have been developed to characterize the potential for reactogenicity in vaccine candidates. Here we describe a refinement of the guinea pig model using an alternate vaccine for positive controls. An initial comparative study used viable C. burnetii to compare the routes of sensitizing exposure of guinea pigs (intranasal vs intraperitoneal), evaluation of two time points for antigen challenge (21 and 42 days) and an assessment of two routes (intradermal and subcutaneous) of challenge using the ruminant vaccine Coxevac as the antigenic control. Animals sensitized by intraperitoneal exposure exhibited slightly larger gross reactions than did those sensitized by intranasal exposure, and reactions were more pronounced when skin challenge was performed at 42 days compared to 21 days post-sensitization. The intradermal route proved to be the optimal route of reactogenicity challenge. Histopathological changes at injection sites were similar to those previously reported and a scoring system was developed to compare reactions between groups receiving vaccine by intradermal versus subcutaneous routes. Based on the comparative study, a standardized protocol for assessment of vaccine reactogenicity in intranasally-sensitized animals was tested in a larger confirmatory study. Results suggest that screens utilizing a group size of n = 3 would achieve 90% power for detecting exposure-related reactogenic responses of the magnitude induced by Coxevac using either of two outcome measures. |
| format | Article |
| id | doaj-art-db26f937517549f8824e279869b89ea7 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-db26f937517549f8824e279869b89ea72025-08-20T03:51:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011310e020588210.1371/journal.pone.0205882Standardized guinea pig model for Q fever vaccine reactogenicity.Laurie A BaetenBrendan K PodellAnn E SluderAnja GarritsenRichard A BowenMark C PoznanskyHistorically, vaccination with Coxiella burnetii whole cell vaccines has induced hypersensitivity reactions in humans and animals that have had prior exposure to the pathogen as a result of infection or vaccination. Intradermal skin testing is routinely used to evaluate exposure in humans, and guinea pig hypersensitivity models have been developed to characterize the potential for reactogenicity in vaccine candidates. Here we describe a refinement of the guinea pig model using an alternate vaccine for positive controls. An initial comparative study used viable C. burnetii to compare the routes of sensitizing exposure of guinea pigs (intranasal vs intraperitoneal), evaluation of two time points for antigen challenge (21 and 42 days) and an assessment of two routes (intradermal and subcutaneous) of challenge using the ruminant vaccine Coxevac as the antigenic control. Animals sensitized by intraperitoneal exposure exhibited slightly larger gross reactions than did those sensitized by intranasal exposure, and reactions were more pronounced when skin challenge was performed at 42 days compared to 21 days post-sensitization. The intradermal route proved to be the optimal route of reactogenicity challenge. Histopathological changes at injection sites were similar to those previously reported and a scoring system was developed to compare reactions between groups receiving vaccine by intradermal versus subcutaneous routes. Based on the comparative study, a standardized protocol for assessment of vaccine reactogenicity in intranasally-sensitized animals was tested in a larger confirmatory study. Results suggest that screens utilizing a group size of n = 3 would achieve 90% power for detecting exposure-related reactogenic responses of the magnitude induced by Coxevac using either of two outcome measures.https://doi.org/10.1371/journal.pone.0205882 |
| spellingShingle | Laurie A Baeten Brendan K Podell Ann E Sluder Anja Garritsen Richard A Bowen Mark C Poznansky Standardized guinea pig model for Q fever vaccine reactogenicity. PLoS ONE |
| title | Standardized guinea pig model for Q fever vaccine reactogenicity. |
| title_full | Standardized guinea pig model for Q fever vaccine reactogenicity. |
| title_fullStr | Standardized guinea pig model for Q fever vaccine reactogenicity. |
| title_full_unstemmed | Standardized guinea pig model for Q fever vaccine reactogenicity. |
| title_short | Standardized guinea pig model for Q fever vaccine reactogenicity. |
| title_sort | standardized guinea pig model for q fever vaccine reactogenicity |
| url | https://doi.org/10.1371/journal.pone.0205882 |
| work_keys_str_mv | AT laurieabaeten standardizedguineapigmodelforqfevervaccinereactogenicity AT brendankpodell standardizedguineapigmodelforqfevervaccinereactogenicity AT annesluder standardizedguineapigmodelforqfevervaccinereactogenicity AT anjagarritsen standardizedguineapigmodelforqfevervaccinereactogenicity AT richardabowen standardizedguineapigmodelforqfevervaccinereactogenicity AT markcpoznansky standardizedguineapigmodelforqfevervaccinereactogenicity |